MDMA enhances hippocampal-dependent learning and memory under restrictive conditions, and modifies hippocampal spine density
- 618 Downloads
Addictive drugs produce forms of structural plasticity in the nucleus accumbens and prefrontal cortex. The aim of this study was to investigate the impact of chronic MDMA exposure on pyramidal neurons in the CA1 region of hippocampus and drug-related spatial learning and memory changes.
Methods and results
Adolescent rats were exposed to saline or MDMA in a regime that mimicked chronic administration. One week later, when acquisition or reference memory was evaluated in a standard Morris water maze (MWM), no differences were obtained between groups. However, MDMA-exposed animals performed better when the MWM was implemented under more difficult conditions. Animals of MDMA group were less anxious and were more prepared to take risks, as in the open field test they ventured more frequently into the central area. We have demonstrated that MDMA caused an increase in brain-derived neurotrophic factor (BDNF) expression. When spine density was evaluated, MDMA-treated rats presented a reduced density when compared with saline, but overall, training increased the total number of spines, concluding that in MDMA-group, training prevented a reduction in spine density or induced its recovery.
This study provides support for the conclusion that binge administration of MDMA, known to be associated to neurotoxic damage of hippocampal serotonergic terminals, increases BDNF expression and stimulates synaptic plasticity when associated with training. In these conditions, adolescent rats perform better in a more difficult water maze task under restricted conditions of learning and memory. The effect on this task could be modulated by other behavioural changes provoked by MDMA.
KeywordsAdolescent rats Brain-derived neurotrophic factor Hippocampus Learning MDMA Spines
The authors acknowledge the Language Advisory Service of the University of Barcelona for revising the language of the manuscript. S. Abad is a fellow of Institut de Biomedicina (IBUB, University of Barcelona). This work was supported by grants from Spanish Ministerio de Ciencia e Innovación (SAF2010-15948, SAF2011-23631 and SAF2012-39852-C02-01) and from the Generalitat de Catalunya (SGR0977).
Conflict of Interest
The authors have no financial or non-financial competing interests in relation to the work described here.
- Angelucci F, Ricci V, Martinotti G, Palladino I, Spalletta G, Caltagirone C, Bria P (2010) Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise of drug-induced psychotic symptoms. Addict Biol 15:365–367PubMedCrossRefGoogle Scholar
- Garcia-Ratés S, Camarasa J, Sánchez-García AI, Gandía L, Escubedo E, Pubill D (2010) The effects of 3,4-methylenedioxymethamphetamine (MDMA) on nicotinic receptors: intracellular calcium increase, calpain/caspase 3 activation, and functional upregulation. Toxicol Appl Pharmacol 244:344–353PubMedCrossRefGoogle Scholar
- Hemmerle AM, Dickerson JW, Herring NR, Schaefer TL, Vorhees CV, Williams MT et al (2012) (±)3,4-Methylenedioxymethamphetamine (“ecstasy”) treatment modulates expression of neurotrophins and their receptors in multiple regions of adult rat brain. J Comp Neurol 520:2459–2474PubMedCentralPubMedCrossRefGoogle Scholar
- Mechan AO, Moran PM, Elliott M, Young AJ, Joseph MH, Green R (2002) A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; “ecstasy”) on the subsequent long-term behavior of rats in the plus maze and open field. Psychopharmacology (Berlin) 159:167–175CrossRefGoogle Scholar
- Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439–452PubMedCentralPubMedCrossRefGoogle Scholar
- Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B et al (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol 27:28–39PubMedCentralPubMedCrossRefGoogle Scholar
- Skelton MR, Able JA, Grace CE, Herring NR, Schaefer TL, Gudelsky GA et al (2008) (+/)-3,4-Methylenedioxymethamphetamine treatment in adult rats impairs path integration learning: a comparison of single vs once per week treatment for 5 weeks. Neuropharmacology 55:1121–1130PubMedCentralPubMedCrossRefGoogle Scholar
- Vorhees CV, Schaefer TL, Skelton MR, Grace CE, Herring NR, Williams MT (2009) (+/−)3,4-Methylenedioxymethamphetamine (MDMA) dose-dependently impairs spatial learning in the Morris water maze after exposure of rats to different five-day intervals from birth to postnatal day twenty. Dev Neurosci 31:107–120PubMedCentralPubMedCrossRefGoogle Scholar
- Vorhees CV, He E, Skelton MR, Graham DL, Schaefer TL, Grace CE et al (2011) Comparison of (+)-methamphetamine, ± − methylenedioxymethamphetamine, (+)-amphetamine and ± −fenfluramine in rats on egocentric learning in the Cincinnati water maze. Synapse 65:368–378PubMedCentralPubMedCrossRefGoogle Scholar